Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease (PREVAIL)
Placebo Controlled, Double Blind, Randomized Cardiovascular Outcome Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With ASCVD Not Adequately Controlled Despite Maximally Tolerated Lipid Modifying Therapies
Sponsor: Monash University
Listed as NCT05202509, this PHASE3 trial focuses on Atherosclerotic Cardiovascular Disease and remains ongoing. Sponsored by Monash University, it has been updated 12 times since 2022, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Study Description(click to expand)This study will be a placebo-controlled, double-blind, randomized, phase 3 study to evaluate the effect of 10mg Obicetrapib in participants with Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately controlled despite maximally tolerated lipid-lowering therapy to reduce the risk of cardiovascular death, myocardial infarction, stroke and non-elective coronary revascularization. The PREVAIL Study
This study will be a placebo-controlled, double-blind, randomized, phase 3 study to evaluate the effect of 10mg Obicetrapib in participants with Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately controlled despite maximally tolerated lipid-lowering therapy to reduce the risk of cardiovascular death, myocardial infarction, stroke and non-elective coronary revascularization. The PREVAIL Study
Status Flow
Change History
12 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE3
▶ Show 7 earlier versions
-
Feb 2024 — Apr 2024 [monthly]
Recruiting PHASE3
-
Feb 2023 — Feb 2024 [monthly]
Recruiting PHASE3
-
Dec 2022 — Feb 2023 [monthly]
Recruiting PHASE3
-
Oct 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Sep 2022 — Oct 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Monash University
- NewAmsterdam Pharma
For direct contact, visit the study record on ClinicalTrials.gov .